1. Market Research
  2. > Ovarian Disease – Pipeline Review, H1 2013

Ovarian Disease – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 30 pages

Ovarian Disease – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Ovarian Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Disease. Ovarian Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ovarian Disease.
- A review of the Ovarian Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ovarian Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Ovarian Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ovarian Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Ovarian Disease - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Ovarian Disease Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Ovarian Disease 7
Ovarian Disease Therapeutics under Development by Companies 9
Ovarian Disease Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Ovarian Disease Therapeutics - Products under Development by Companies 13
Ovarian Disease Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Ovarian Disease Therapeutics Development 15
IBSA Institut Biochimique SA 15
Respiratorius AB 16
Ovarian Disease - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
SPOC - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Merional - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
PTEN Inhibitor - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
degarelix - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Recombinant Humam Serum Albumin Biosimilar - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Gonadotropin-Releasing Hormone Antagonists - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Ovarian Disease Therapeutics - Dormant Products 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30



List of Tables

Number of Products Under Development for Ovarian Disease, H1 2013 7
Products under Development for Ovarian Disease - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 14
IBSA Institut Biochimique SA, H1 2013 15
Respiratorius AB, H1 2013 16
Assessment by Monotherapy Products, H1 2013 17
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Stage and Molecule Type, H1 2013 21
Ovarian Disease Therapeutics - Dormant Products 28



List of Figures

Number of Products under Development for Ovarian Disease, H1 2013 7
Products under Development for Ovarian Disease - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Discovery and Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 17
Assessment by Route of Administration, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Molecule Type, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.